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Background: Implantation of xenogenic chromaffin cells into the spinal subarachnoid space can produce analgesia 
in neuropathic pain models. However, transplantation of xenogeneic chromaffin cell has a potential risk of viral or 
bacterial infections from animals to humans including encephalopathy due to prion transmission. The aim of this 
study was to investigate the possibility of developing a homogeneic source of therapeutic chromaffin cells. 
Methods: Anti-allodynic effects of human chromaffin cells (HCCs) were evaluated in a neuropathic pain model 
in rats induced by chronic constriction injury of the sciatic nerve. HCCs encapsulated with alginate-poly-L-lysine-
alginate were intrathecally implanted into rats (n = 10), while empty capsules were intrathecally implanted as a 
control (n = 8). Levels of norepinephrine from encapsulated HCCs before and after nicotinic stimulation were 
measured. We then perfomed a behavior test (cold allodynia) with acetone. In addition, to assess the potential 
contribution to pain reduction of opioid peptides released from the HCCs, all animals were injected with naloxone. 
Results: The concentration of norepinephrine after nicotine stimulation was significantly increased compared to 
basal levels. Intrathecal implantation of encapsulated HCCs, significantly reduced cold allodynia as compared to 
rats receiving empty capsules (P < 0.05). Fifteen minutes after the injection of naloxone, cold allodynia significantly 
decreased in rats with HCCs (P < 0.05), while the degree of cold allodynia in control animals was unaltered. 
Conclusions: From these results, it appears that HCCs have a possibility as an analgesic source for transplants 
delivering pain-reducing neuroactive substances. (Korean J Anesthesiol 2011; 60: 357-361)
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Introduction
    Despite recent advances in our understanding of chronic pain 
mechanisms, the management of chronic pain, particularly 
neuropathic pain, is far from being resolved with currently 
available therapeutic regimens. Therefore, chronic pain is a 
major medical and societal problem that results in enormous 
financial costs [1,2]. Transplantation of cells that secrete 
neuroactive substances with analgesic properties into the 
central nervous system (CNS) has been considered to be a 
promising therapy for the long-term treatment of chronic pain 
[3,4]. Intrathecally administered bovine adrenal chromaffin 
cells were reported to reduce neuropathic pain in rats by 
producing antinociceptive substances, such as catecholamines 
and met-enkephalin [5,6]. 
    Due to the low number of available grafts, sources other than 
human cells, that is xenogenic donors have to be considered for 
this therapeutic approach [5,6]. However, the major problem 
associated with xenogenic cell transplantation has been the 
long-term survival of the transplanted cells and the risk of the 
infection from viruses or pathogens, such as mad cow disease. 
Therefore, homologous transplant may be one of the safest 
methods for clinical applications. In this study, we investigate 
the analgesic effect of human chromaffin cells (HCCs) on 
neuropathic pain in rats with chronic constrictive injury (CCI) 
of the sciatic nerve. 
Materials and Methods
    Approval was obtained from our Ethics Committee, and 
written informed consent was obtained from all patients. 
The study protocol was also approved by our Animal Care 
Committee. 
Purification of HCCs
    Adrenal chromaffin glands from the adrenal mass of patients 
with renal cell cancer were isolated and transported at 4
oC in 
Locke's solution (154 mM NaCl, 5.6 mM KCl, 3.6 mM NaHCO3, 
5.6 mM glucose, and 5 mM HEPES) to the laboratory within 
1 h. After removing connective tissue and blood vessels using 
an aseptic technique, the exterior surfaces of the exposed 
adrenal glands were rinsed and perfused with Locke's solution 
including 1% penicillin/streptomycin (10,000 unit/ml; Gibco, 
Carlsbad, CA, USA). The glands were then incubated in 
digestion buffer (0.2% [wt/vol] collagenase, Worthington, 
Lakewood, NJ, USA in Locke's solution) at 37
oC for 20 min. The 
adrenal medullary tissue was dissected from the surrounding 
cortical tissue, triturated, and incubated in digestion buffer at 
37
oC for 1 h. The digested medullary tissue was then passed 
through a polypropylene screen (100 μm mesh). The cell 
suspension was centrifuged for 5 min at 70 × g in 40 ml Locke's 
solution. The supernatant was discarded and the cell pellet was 
resuspended and centrifuged for 5 min. The cell pellet was then 
resuspended in Dulbecco's Modified Eagle's Medium (DMEM)/
F12 (Invitrogen, Grand Island, NY, USA) supplemented with 
10% fetal bovine serum (FBS, Invitrogen) and inoculated into 
non-tissue culture dishes at a density of  ~5 × 10
6 cells/dish. The 
cells were incubated at 37
oC (5% CO2) in a humidified, enriched 
environment overnight to allow for differential adherence of 
unwanted cell types such as fibroblasts and endothelial cells. 
The next day, the less adherent chromaffin cells were separated 
by gentle agitation and were plated into non-tissue culture-
treated Petri dishes at the same density after centrifugation at 80 
× g at 25
oC for 10 min.
    The procedure was repeated once again to obtain highly 
purified chromaffin cells and replated into tissue culture-
treated dishes at the same density in DMEM/F12 including 10% 
FBS, antibiotics (100 μM/ml penicillin/streptomycin, Gibco), 
and antimytotic agents (10
-5 M uridine and 10
-5 M 5-fluoro5-
deoxyurdine, Sigma-Aldrich, St. Louis, MO, USA). A 10 μl 
aliquot of cells was stained with trypan blue solution (0.2%) and 
counted in a hemocytometer to estimate both yield and cell 
viability. To confirm the purification of HCCs, a 10 μl aliquot 
was stained with neutral red (0.9% in phosphate buffered 
solution), a dye that selectively reacts with monoamine-
containing cells. In all, 95% HCCs were obtained through the 
multiple purification process.
Norepinephrine
    Function of HCCs inside the capsules was evaluated by 
measuring the release of catecholamine by nicotine stimulation 
in vitro for 30 days. At various times during cell culture, 
microencapsulated HCCs were incubated in 12-well plates 
at a density of 1 × 10
6 cells/well and washed three times with 
HBSS (Hanks' balanced salt solution, Gibco) containing 50 μM 
ascorbic acid. They were incubated in 1 ml HBSS for 60 min at 
37
oC to obtain basal levels of catecholamines. These samples 
were collected, filtered with 0.2 μm filter and immediately 
frozen in at -70
oC. After basal sampling, HCCs were incubated 
in 1 ml HBSS with 50 μM nicotine for 60 min under the same 
condition as the basal samples. Catecholamine levels were 
quantified using reverse phase high-performance liquid chro-
mato  graphy (HPLC, BAS-480; Bioanalytical Systems, West 
Lafayette, IN, USA) with electrochemical detection. The mobile 
phase was 0.07 M NaH2PO4, 0.2 mM octylsodium sulfate, 
0.1 mM EDTA, and 8% methanol. The flow rate through a 
Waters Resolve C18μ Bondapak column was 1.0 ml/min. The 
electrochemical detector was set at +0.6 mV versus an Ag-AgCl 359 www.ekja.org
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reference electrode.
Microencapsulation of HCCs
    After 3-4 days of primary culture, HCCs were suspended in 
1.4% (wt/vol) sodium alginate (Junsei, Tokyo, Japan) and 0.85% 
NaCl at a density of 5,106 cells/ml. Spherical droplets of this 
suspension were formed by extrusion through a syringe pump 
and gelled in 1.1% CaCl2. Cell capsules were microcapsules 
having a diameter ranging from 100-300 mm. After washing 
twice in 0.85% NaCl, the capsules were coated with 0.05% 
poly-l-lysine (Sigma, St. Louis, MO, USA). The coated capsules 
were washed with 0.85% NaCl and then suspended for 7 min 
in 0.12% sodium alginate, which formed the outer layer of the 
membrane. After another wash with 0.85% NaCl, the capsules 
were then treated with 1 mM sodium citrate (pH 7.4) for 2 
min. The sodium citrate was removed by washing twice with 
0.85% NaCl and the encapsulated cell suspension was then 
distributed equally into 6-well culture dishes with DMEM/
F12 supplemented with 10% FBS. The encapsulated cells were 
maintained at 37
oC (95% relative humidity, 5% CO2). 
    Animals: Male Sprague-Dawley rats (200 to 300 g, Taconic) 
were group-housed with two per polycarbonate cage, in a 
temperature controlled room with a 12 : 12-hour light/dark 
cycle. Food and water were available ad libitum. All surgical 
procedures were performed by trained surgeons using 
aseptic techniques and anesthesia (pentobarbital, 50 mg/kg 
intraperitoneally, supplemented as necessary).
    Neuropathic pain model: For the CCI surgery, the left 
common sciatic nerve was exposed at the mid-thigh level under 
25x magnification. Four ligatures of size 40 chromic gut were 
tied loosely around the nerve with 1 mm spacing between knots 
so that the epineural circulation was preserved. At the time of 
tying, the ligatures just barely reduced the nerve diameter [7]. 
Over time, the ligatures evoked intraneural edema, resulting in 
constriction of the nerve. After surgery, the wound was washed 
with saline and the layers (fascia and skin) were closed with size 
30 silk thread. 
    Implantation: One week after CCI surgery, rats were 
randomly allocated into the two groups. The cell loaded group 
received encapsulated chromaffin cells (n = 10), while control 
group received empty capsules (n = 8). The microcapsules were 
implanted into the lumbar subarachnoid space. A posterior 
L5 laminectomy was performed and then a small incision was 
made in the dura. Approximately 500 microcapsules (5 × 10
2 
cells/capsule) were implanted into the subarachnoid space via 
a 24-gauge teflon catheter. After surgery, the wound was washed 
with saline and the layers (fascia and skin) were closed with size 
30 silk thread. 
    Cold allodynia: A drop of acetone solution (97.7%) was 
applied under the hind paw:acetone evaporates quickly 
producing a sensation of cold. The duration of the withdrawal 
response (cold allodynia) was recorded with an arbitrary 
minimum value of 0.5 s and a maximum value of 40 s.
    Opioid antagonist (Naloxone): To assess the potential 
contribution to pain reduction by opioid peptides released 
from the implanted microcapsules, all animals were injected 
with the opioid antagonist, naloxone, during the peak period of 
analgesia exerted by the chromaffin cells. Following behavioral 
testing 3 weeks after nerve ligation (2 weeks after implantation), 
the animals were injected with naloxone (2.0 mg/kg, S.C.). 
Fifteen minutes later, the degree of cold allodynia was assessed. 
    Data analysis: Results are reported as means ± SD. Statistical 
analysis of the cold allodynia data was performed using SPSS 
for Windows version 10.0 (SPSS Inc., Chicago, IL). We applied 
a student t test to compare the values from two independent 
samples and a paired t test to compare the values of means from 
two related samples. Statistical significance was considered 
when P < 0.05. 
Results
Norepinephrine
    Quantities of norepinephrine are shown in Fig. 1. The concen-
tration of norepinephrine after nicotine stimulation was signifi-
cantly increased compared to basal levels (P < 0.05). 
Cold allodynia
    As shown in Fig. 2, animals exhibited little or no response to a 
Fig. 1. Norepinephrine release from encapsulated human 
chromaffin cells in vitro. The levels of norepinephrine in Hank’s 
buffered salt solution (HBSS) were evaluated 1, 7, 14, and 30 days 
after encapsulation by HPLC. *P < 0.05 compared with pre-nicotine 
stimulation.360 www.ekja.org
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cold stimulus (acetone) prior to ligation of the sciatic nerve. One 
week after nerve ligation, there was an enhanced withdrawal 
response to acetone evaporation. After the implantation of 
microencapsulated HCCs, the response duration was signifi-
cantly reduced as compared to the controls which received 
empty microcapsules (P < 0.05, Fig. 2).
Opioid antagonist test 
    As shown in Fig. 3, fifteen minutes after the injection of 
naloxone, the degree of cold allodynia in control animals was 
unaltered. However, cold allodynia significantly increased after 
naloxone injection in rats with HCCs (P < 0.05). The severity 
of cold allodynia in rats with HCCs was less than in the control 
animals (P < 0.05). 
Discussion
    We observed that, in vitro, nicotine induced a significant 
release of catecholamine from HCCs, and in vivo, we observed 
a significant decrease in cold allodynia in rats implanted with 
HCCs. Chromaffin cells that release various pain suppressing 
substances originate from ectoderm of the neural crest [8]. 
Therefore, the possibility of an immune reaction is low within 
the central nerve system, making the chromaffin cells suitable 
for transplant in subarachnoid space. In addition, the blood-
brain-barrier exists in the subarachnoid space which makes 
them immuno-privileged [9]. Although intrathecally implanted 
xenogenic chromaffin cells produced analgesic effects in the 
neuropathic pain models [10], there is a possibility of rejection 
of these xenogenic implants by the host. In addition, xenogenic 
implants can be a source of viral infection or pathogens. Thus, 
homologous transplant is considered one of the safest methods 
despite donor limitation. 
    To protect HCCs from the immune cells of rat, HCCs were 
capsulated within a semipermeable polymer membrane made 
of alginate-poly-L-lysine-alginate (APA) [6,11]. Additionally, 
this isolation method forms a proper environment for survival 
of the implant by allowing diffusion of oxygen, nutrients 
and growth factors from the host into the implant, as well as 
allows the discharge of waste biproducts out of the HCCs. The 
encapsulation has two strategies: the first is macrocapsulation 
which encloses cells into a flat sheet membrane with a semi-
permeable nature [12] and the other is microcapsulation which 
encloses cells into round-shaped mini capsules [6,11,13,14]. 
However, microcapsules may be a superior system for cell 
transplantation than macrocapsules for delivery of therapeutic 
substances and long-term survival [6]. 
    In this study, we observed that cold allodynia in rats 
implanted with HCCs was significantly lower 3 to 30 days 
after transplantation when compared with the control group. 
In addition, the encapsulated HCCs in vitro significantly 
produced norepinephrine after nicotine stimulation up to 30 
days after encapsulation. With his finding, we presumed that 
microencapsulated chromaffin cells were able to produce high 
levels of catecholamines in the long term, thereby potentially 
reducing pain. Indeed, norepinephrine in the spinal cord 
induces analgesia in the several animal pain models [15,16]. 
Descending inhibitory tracts originating from cell bodies in the 
periaqueductal gray,reticular formation and nucleus magnus 
project spinal dorsal horn. These inhibitory tracts contain a 
Fig. 2. Rats developed a cold allodynic response to acetone after 
ligation of the sciatic nerve. Rats that received microencapsulated 
human chromaffin cells showed a significant decrease in the 
withdrawal response to acetone, as compared to the control group 
(*P < 0.05). The data are presented as means ± SD. Significant 
withdrawal time differences between the cell transplantation and 
control groups were seen (*P < 0.05 vs Control).
Fig. 3. Effect of naloxone on the degree of cold allodynic response 
to acetone after nerve ligation in rats with microencapsulated 
chromaffin cells. *P < 0.05 compared to pre-injection of naloxone (2.0 
mg/kg, S.C.). The data are presented as means ± SD.361 www.ekja.org
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variety of neurotransmitters including catecholamines and 
opioids, which play an important role in nociceptive responses 
[17,18]. In this study, after naloxone administration, the 
withdrawal duration time from acetone in rats with implanted 
HCCs significantly increased. From these data, we speculate 
that one of analgesic materials released from HCCs may be an 
opioid peptide such as met enkephalin [5,6]. 
    In conclusion, although HCCs has the limitation of supply, 
they have the advantage of decreased infection risk and tissue 
rejection resulting from heterologous transplant. Therefore, 
this could become a new therapy for pain treatment with 
guaranteed stability and effective pain suppression when 
transplanted into the human body. 
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